Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism

被引:21
|
作者
Akizawa, T
Ohashi, Y
Akiba, T
Suzuki, M
Nishizawa, Y
Ogata, E
Slatopolsky, E
Kurokawa, K
机构
[1] Wakayama Med Univ, Ctr Blood Purificat Therapy, Wakayama 6410012, Japan
[2] Univ Tokyo, Sch Hlth Sci & Nursing, Dept Biostat, Tokyo, Japan
[3] Tokyo Womens Med Univ, Kidney Ctr, Div Blood Purificat, Tokyo, Japan
[4] Shinrakuen Hosp, Dept Internal Med, Niigata Soc Serv Org, Social Welf Dept, Niigata, Japan
[5] Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka 558, Japan
[6] Fdn Canc Res Hosp, Tokyo, Japan
[7] Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA
[8] Tokai Univ, Inst Med Res, Isehara, Kanagawa, Japan
关键词
D O I
10.1111/j.1774-9987.2004.00191.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The dose-response relationships and the safety of administering 22-oxacalcitriol (OCT) to patients with secondary hyperparathyroidism (2HPT) under regular three-times-weekly hemodialysis (HD) were evaluated by double-blind parallel group design. A total of 203 patients with 2HPT were randomly allocated into four groups, and 5 mug (Group L), 10 mug (Group M), or 15 mug (Group H) OCT, or placebo (Group P) was administrated at the end of every HD for 12 weeks. Reductions of intact-parathyroid hormone (iPTH) concentration greater than 30% from baseline were observed in 7.7% of Group P as compared to 77.3% of the pooled OCT groups after 12 weeks of treatment (Mantel test: P<0.001). Time-trends (slopes) of log-iPTH concentration calculated by least-squares line fitting to each patient's data during treatment differed between Group P and the pooled OCT groups (t-test: P < 0.001) and these iPTH slopes decreased dose-dependently (linear trend by t-test: P < 0.001). Slopes of serum calcium corrected for albumin (corrected-sCa) concentrations also differed between Group P and the pooled OCT groups (t-test: P < 0.001), and increased dose-dependently (linear trend by t-test: P < 0.0001). Serum phosphorus and Ca x P product increased significantly only in high dose groups. Slopes of log(iPTH) and corrected-sCa concentrations were reciprocally related. Most adverse events were hypercalcemia and dose-related, but occasionally comprised pruritus or increased serum creatinine phosphokinase. These results indicate that OCT produced a strong and dose-dependent suppression of PTH and an increase of corrected-sCa concentration in patients with 2HPT. The recommended initial dosages of OCT would appear to be 5 mug when pretreatment iPTH concentrations are less than 500 pg/mL, and 10 mug when greater than 500 pg/mL for safe and effective treatment. As in the case of PTH, calcium and phosphorus showed dose-dependent increases. It is therefore essential to take precautions as to possible increases in calcium and phosphorus.
引用
收藏
页码:480 / 491
页数:12
相关论文
共 50 条
  • [1] Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients
    Doi, S
    Yorioka, N
    Usui, K
    Shigemoto, K
    Harada, S
    INTERNAL MEDICINE, 2003, 42 (10) : 955 - 959
  • [2] SUPPRESSION OF PTH BY 22-OXACALCITRIOL IN HEMODIALYSIS-PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
    KUROKAWA, K
    AKIZAWA, T
    SUZUKI, M
    AKIBA, T
    OGATA, E
    SLATOPOLSKY, E
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 966 - 966
  • [3] Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
    Kurokawa, K
    Akizawa, T
    Suzuki, M
    Akiba, T
    Ogata, E
    Slatopolsky, E
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 : 121 - 124
  • [4] Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism
    Tsukamoto, Y
    Hanaoka, M
    Matsuo, T
    Saruta, T
    Nomura, M
    Takahashi, Y
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (03) : 458 - 464
  • [5] Clinical trial of 22-oxacalcitriol in chronic hemodialysis patients with secondary hyperparathyroidism.
    Yamamoto, H
    Kusano, E
    Masunaga, Y
    Okuda, K
    Takeda, S
    Ito, C
    Ando, Y
    Muto, S
    Asano, Y
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 754A - 755A
  • [6] Suppression of PTH by 22-oxacalcitriol (OCT). A placebo controlled double blind study in hemodialysis (HD) patients with secondary hyperparathyroidism (2 HPT).
    Akizawa, T
    Kurokawa, K
    Suzuki, M
    Akiba, T
    Nishizawa, Y
    Ohashi, Y
    Ogata, E
    Slatopolsky, E
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A2655 - A2655
  • [7] Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism
    Ogata, Hiroaki
    Koiwa, Fumihiko
    Shishido, Kanji
    Takahashi, Keiko
    Ito, Hidetoshi
    Kinugasa, Eriko
    Taguchi, Susumu
    THERAPEUTIC APHERESIS AND DIALYSIS, 2007, 11 (03) : 202 - 209
  • [8] 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure
    Monier-Faugere, MC
    Geng, ZP
    Friedler, RM
    Qi, QL
    Kubodera, N
    Slatopolsky, E
    Malluche, HH
    KIDNEY INTERNATIONAL, 1999, 55 (03) : 821 - 832
  • [9] A NOVEL NON-CALCEMIC VITAMIN-D ANALOG 22-OXACALCITRIOL (OCT) FOR THE TREATMENT OF HYPERPARATHYROIDISM
    BROWN, A
    RITTER, C
    MORRISSEY, J
    FINCH, J
    MARTIN, K
    MURAYAMA, E
    NISHII, Y
    SLATOPOLSKY, E
    CLINICAL RESEARCH, 1989, 37 (02): : A569 - A569
  • [10] Suppressive effect of 22-oxacalcitriol (OCT) on secondary hyperparathyroidism (2 HPT) of hemodialysis (HD) patients. A double-blind comparison among four doses.
    Akizawa, T
    Kurokawa, K
    Suzuki, M
    Akiba, T
    Nishizawa, Y
    Ohashi, Y
    Ogata, E
    Slatopolsky, E
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A2818 - A2818